A Comprehensive Guide to Sodium Glucose Cotransport Inhibitors

Document Type

Article

Publication Date

5-19-2023

Publication Title

Current problems in cardiology

Abstract

Sodium-glucose cotransport 2 inhibitors (SGLT2i) are a class of drugs initially approved by the Food and Drug Association (FDA) as antihyperglycemic agents for patients with type 2 diabetes mellitus (DM). However, lately, these agents (Canagliflozin, Empagliflozin, Ertugliflozin, Sotagliflozin, and Dapagliflozin) have become better known for their cardiovascular (CV) and reno-protective effects. In this comprehensive review and analysis, we display the advancement of Sodium Glucose Cotransport Inhibitors have shown in cardiology, specifically heart failure in a concise, yet thorough manner.

PubMed ID

37211299

Volume

48

Issue

10

First Page

101817

Last Page

101817

Find It @ Sladen

Share

COinS